Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Vibegron Patent Expiration

Vibegron is Used for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It was first introduced by Urovant Sciences Gmbh in its drug Gemtesa on Dec 23, 2020.


Vibegron Patents

Given below is the list of patents protecting Vibegron, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Gemtesa US12102638 Use of vibegron to treat overactive bladder Mar 22, 2040 Urovant
Gemtesa US8247415 Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists Dec 01, 2030 Urovant
Gemtesa US8653260 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists Apr 02, 2029 Urovant



Vibegron's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Vibegron:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Vibegron has 3 clinical trials that have been verified in 2024.

Title Lead Sponsor Collaborators Status Phases
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC Urovant Sciences GmbH RECRUITING
(Jul, 2024)
 PHASE2, PHASE3
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) Urovant Sciences GmbH COMPLETED
(Jun, 2024)
 PHASE3
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia Urovant Sciences GmbH COMPLETED
(Jun, 2024)
 PHASE3
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome Urovant Sciences GmbH COMPLETED
(Jul, 2021)
 PHASE2
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) Urovant Sciences GmbH COMPLETED
(Feb, 2021)
 PHASE3
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Urovant Sciences GmbH COMPLETED
(Feb, 2021)
 PHASE3
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) Merck Sharp & Dohme LLC COMPLETED
(Jan, 2019)
 PHASE2
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) Merck Sharp & Dohme LLC TERMINATED
(Dec, 2018)
 PHASE1
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) Merck Sharp & Dohme LLC COMPLETED
(Dec, 2018)
 PHASE1
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) Merck Sharp & Dohme LLC COMPLETED
(Dec, 2018)
 PHASE1